Shares of MiniMed Group Inc (NASDAQ:MMED - Get Free Report) have been given an average rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $21.6154.
MMED has been the topic of a number of research analyst reports. Wells Fargo & Company dropped their price target on MiniMed Group from $26.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, June 4th. UBS Group started coverage on shares of MiniMed Group in a research note on Tuesday, July 28th. They issued a "buy" rating and a $25.00 target price for the company. Piper Sandler restated a "neutral" rating and set a $16.00 price target on shares of MiniMed Group in a research note on Thursday, June 4th. Benchmark reissued a "buy" rating on shares of MiniMed Group in a research report on Thursday, June 4th. Finally, Bank of America lowered their price target on MiniMed Group from $27.00 to $20.00 and set a "buy" rating for the company in a research report on Monday, May 18th.
Get Our Latest Stock Report on MMED
MiniMed Group Price Performance
Shares of MMED stock opened at $18.05 on Monday. The company has a market cap of $5.07 billion and a price-to-earnings ratio of -26.54. MiniMed Group has a 52-week low of $10.65 and a 52-week high of $20.48. The business's 50 day simple moving average is $14.96.
MiniMed Group (NASDAQ:MMED - Get Free Report) last posted its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. The business's quarterly revenue was up 15.6% compared to the same quarter last year.
About MiniMed Group
(
Get Free Report)
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiniMed Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiniMed Group wasn't on the list.
While MiniMed Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.